This information is intended for visitors outside of the United States
Click here for US visitors
This information is intended for visitors outside of the United States
Dr Carl June, Dr Claire Roddie and Dr Yi Lin provide an overview of how the CAR T landscape will evolve in the future
Dr Natasha Kekre of The Ottawa Hospital, Ottawa, Ontario, Canada reviews clinical trial data and real-world evidence for CAR T in 2L DLBCL, highlighting the importance of early referral
Dr Pierre Sesques of the Lyon University Hospital, Lyon, France summarises the typical CAR T journey, emphasising the value of referral–treatment centre collaboration
Dr Pierre Sesques discusses key considerations for coordinating long-term patient care post CAR T. Prof. Graham Collins and Dr Mariana Bastos-Oreiro close the symposium by summarising the key discussion points
Explore the Kite Cell Therapy Hub for tailored, on-demand videos and resources to further your knowledge, understanding of the data relating to CAR T and practical skills throughout the CAR T-cell journey: from the identification of appropriate patients who may benefit from CAR T-cell therapy and timely referral, to patient communication and optimisation, as well as post CAR T management and follow-up.
Dr Miguel-Angel Perales, Memorial Sloan Kettering Cancer Center, New York, USA, reviews ZUMA-7's overall survival outcomes with axicabtagene cilolucel▼ in the treatment of R/R DLBCL and its potential implications for bridging strategies
Prof. Marie José Kersten introduces the symposium which focuses on improving outcomes in relapsed refractory DLBCL
Explore suggested content tailored to your role within the CAR T-cell therapy journey
Be the first to find out about Kite Cell Therapy Hub's upcoming content launches
▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.
Reporting of side effects
If you get any side effects, talk to your doctor or nurse. In Great Britain and Northern Ireland, you can also report side effects directly via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. You can also report side effects and quality complaints to Gilead. For information now how to report a side effect in another country, click here. By reporting side effects, you can help provide more information on the safety of this medicine.
